Puig Luis, Sewerin Philipp, Schuster Christopher, Ng Khai Jing, Papadimitropoulos Manny, Gadagamma Sneha, Nuñez Mercedes, Lampropoulou Anastasia
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
University Hospital of the Ruhr, University Bochum, Bochum, Germany.
Adv Ther. 2025 Jul 17. doi: 10.1007/s12325-025-03258-9.
To describe the results of a systematic literature review of real-world outcomes with ixekizumab in psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA).
Databases, conference proceedings, and additional sources were searched for real-world studies in ≥ 25 patients treated with ixekizumab for PsO, PsA, or axSpA. Data on clinical effectiveness, patient-reported outcomes, treatment patterns, safety, and economic burden were extracted.
A total of 118 publications were included, 96 in PsO, 16 in PsA, 5 in both PsO and PsA, and 1 in axSpA. Most focused on clinical effectiveness and treatment patterns. Ixekizumab was effective in real-world settings, and the anti-interleukin (IL)-17A biologics were more effective for skin clearance than comparator biologics. Anti-IL-17A biologics were effective for challenging body areas (nails, scalp, genitals, palmoplantar regions), and ixekizumab was associated with a higher chance of obtaining Dermatology Life Quality Index scores of 0/1 than secukinumab or other biologics. Ixekizumab was associated with generally high persistence/drug survival. No unexpected safety signals were identified.
Real-world ixekizumab use for PsO and PsA is effective and safe, with a positive impact on patient quality of life. More data are needed to draw conclusions for real-world ixekizumab use in axSpA.
描述一项关于以司库奇尤单抗治疗银屑病（PsO）、银屑病关节炎（PsA）或中轴型脊柱关节炎（axSpA）的真实世界疗效的系统文献综述结果。
检索数据库、会议论文集及其他来源，查找≥25例接受司库奇尤单抗治疗PsO、PsA或axSpA的真实世界研究。提取有关临床疗效、患者报告结局、治疗模式、安全性和经济负担的数据。
共纳入118篇出版物，其中96篇关于PsO，16篇关于PsA，5篇同时涉及PsO和PsA，1篇关于axSpA。大多数研究聚焦于临床疗效和治疗模式。司库奇尤单抗在真实世界环境中有效，抗白细胞介素（IL）-17A生物制剂在清除皮肤方面比对照生物制剂更有效。抗IL-17A生物制剂对具有挑战性的身体部位（指甲、头皮、生殖器、掌跖部位）有效，且与司库奇尤单抗相比，司库奇尤单抗获得皮肤病生活质量指数评分为0/1的可能性更高。司库奇尤单抗的持续用药/药物留存率总体较高。未发现意外的安全信号。
司库奇尤单抗在PsO和PsA的真实世界应用中有效且安全，对患者生活质量有积极影响。需要更多数据才能得出司库奇尤单抗在axSpA真实世界应用中的结论。
